Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $546K rose 9.0% year over year, ahead of the +4.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +22.0% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +9.0% holds above the trailing-twelve-month pace of +4.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.08M USD
- Year-over-year change
- +3.8%
- 4-year CAGR
- +255.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.08M | +3.8% |
| FY2024 | 2024-12-31 | 2M | +8.6% |
| FY2023 | 2023-12-31 | 1.84M | +61.0% |
| FY2022 | 2022-12-31 | 1.15M | +8707.7% |
| FY2021 | 2021-12-31 | 13K | — |
Depreciation & Amortization vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's LTM Mar 2026 depreciation & amortization of $2.12M is the 6th highest of the 11 companies compared; the peer median is $2.29M.
- Its year-over-year change of +4.8% is the 6th highest of 10, against a peer median of +15.6%.
- Over three fiscal years its annual growth of +22.0% compares with a peer median of +3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1B | +66925.2% | +52.5% | — | |
| LTM Mar 2026 | $13.46M | +95.4% | +63.4% | 6.2% | |
| LTM Mar 2026 | $12.36M | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $3.98M | -12.6% | -13.1% | 10.9% | |
| LTM Mar 2026 | $2.93M | -1.6% | -0.7% | 1.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.12M | +4.8% | +22.0% | — |
| LTM Mar 2026 | $1.65M | -13.9% | +19.6% | — | |
| LTM Mar 2026 | $1.25M | +15.6% | +8.7% | 249.7% | |
| LTM Mar 2026 | $577.79K | — | +4.5% | 62.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $328K | +19.3% | -0.6% | — |
| LTM Mar 2026 | $326K | +0.0% | +3.2% | — | |
| Peer median (excluding LXEO) | $2.29M | +15.6% | +3.9% | 10.9% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.66M | 654K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.66M | 654K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 45.12M | 49.16M | 53.13M | 74.09M | 63.8M |
| Selling, General & Admin | 7.17M | 12M | 15.38M | 31.68M | 45.46M |
| Operating Expenses | 52.29M | 61.16M | 68.51M | 105.77M | 109.26M |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 2.08M |
| EBITDA | (50.61M) | (58.04M) | (64.35M) | (96.19M) | (97.68M) |
| EBITDA Margin | -3054.3% | -8874.8% | — | — | — |
| Operating Income | (50.64M) | (60.51M) | (68.51M) | (105.77M) | (109.26M) |
| Operating Margin | -3055.9% | -9252.1% | — | — | — |
| Interest Income | 15K | 1.33M | 2.87M | 7.56M | 6.13M |
| Interest Expense | 0 | 91K | 205K | 114K | 206K |
| Other Income / Expenses | 15K | 1.23M | 2.12M | 7.43M | 9.3M |
| Income Before Tax | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Pre-Tax Margin | -3055.0% | -9063.8% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Net Margin | -3055.0% | -9063.8% | — | — | — |
| EPS (Basic) | (2.01) | (2.36) | (2.49) | (3.09) | (1.86) |
| EPS (Diluted) | (2.01) | (2.40) | (2.49) | (3.09) | (1.86) |
| Weighted Avg Shares | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
| Weighted Avg Shares (Diluted) | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.